Back to search

Article

Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective study

2023-07-05

Abstract excerpt

<h4>Background</h4> Limited data are available on the application of circulating tumor DNA (ctDNA) in metastatic triple-negative breast cancer (mTNBC) patients. Here, we investigated the value of ctDNA for predicting the prognosis and monitoring the treatment response in mTNBC patients. <h4>Methods</h4> We prospectively enrolled 70 Chinese patients with mTNBC who had progressed after ≤ 2 lines of chemotherapy an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
749a1e2f-7b0f-556f-a0b3-78ba773579cf
DOI
10.1101/2023.07.04.23292206
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dynamic Analysis of Circulating Tumor DNA to Predict the Prognosis and Monitor the Treatment Response of Patients with Metastatic Triple-negative Breast Cancer: a prospective studyDOI 10.1101/2023.07.04.23292206
Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.Semantic proximity
Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity
Dynamic ctDNA tracking stratifies individual relapse risk for early triple negative breast cancer patients receiving neoadjuvant chemotherapySemantic proximity
Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity
Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer PatientsSemantic proximity
Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast CancerSemantic proximity
Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncologySemantic proximity
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapySemantic proximity
Individualized ctDNA Fingerprints to Monitor Treatment Response and Recurrence in Multiple Cancer TypesSemantic proximity
Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity
Select a neighboring publication to make it the new centre.